Physician profile
Daniel Jeffrey Behn
NPI 1093719775
$2,956.88
in general payments reported to CMS, 2019-2025
21 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $185 · 2021: $366 · 2022: $413 · 2023: $406 · 2024: $633 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $565.26 | 2021-2025 | Tearcare System, Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $455.83 | 2020-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $294.17 | 2021-2025 | Clareon, Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $284.92 | 2022-2025 | Biotrue One Day, Vyzulta, Scoutpro Osmolarity System |
| Notal Vision, INC. | $244.14 | 2024-2025 | Foresee Home |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $123.37 | 2019-2021 | |
| Ocular Therapeutix, INC. | $122.21 | 2023-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $109.30 | 2022-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $101.71 | 2019 | |
| Biotissue Holdings INC. | $92.95 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $87.84 | 2023-2024 | Acthar |
| Dompe US, INC. | $80.14 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $72.55 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $69.14 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $53.05 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $46.74 | 2022-2024 | Ryzumvi, Tyrvaya |
| Harrow Eye, LLC | $41.52 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $33.96 | 2021-2022 | |
| Amgen INC. | $28.42 | 2025 | Tepezza |
| Astellas Pharma US INC | $26.28 | 2023 | |
| Abbvie INC. | $23.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Behn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.